Abstract
Background: For resectable Stage IA2 to IIB (T1b-T3N0) NSCLC, the current practice is surgery followed by observation for Stage IA disease. Adjuvant platinum-based doublet chemotherapy is offered to patients (pts) with stage IB disease with high-risk pathological and radiological features and is recommended for those with Stage II NSCLC. In pts with resected lung cancer, post-operative ctDNA predicts and precedes radiographic recurrences. The survival benefit seen with 1st-line chemo-immunotherapy (chemo-IO) for advanced NSCLC provided the rationale to launch this trial offering concurrent immunotherapy with adjuvant chemo to selected pts.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
